German National Cancer Guidelines Distinguish Oncotype DX® as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence

Updated Guidelines Elevate Evidence following Publication of Multiple Large Prospective Outcomes Studies.

Genomic Health, Inc. announced the update of the German Association of Gynecological Oncology's (AGO's) treatment guidelines to recognize Oncotype DX® as the only multi-gene breast cancer test with the highest 1A level of evidence. The AGO guidelines also reconfirmed Oncotype DX as the only multi-gene expression test validated to provide predictive information on the likelihood of chemotherapy benefit for women with early-stage, hormone-receptor positive, HER2-negative invasive breast cancer.

"The latest update by AGO supports public reimbursement in Germany, one of our key European markets, and furthers international growth as we continue to bring precision medicine to breast cancer patients worldwide," said Jim Vaughn, R.Ph. Chief Commercial Officer, Genomic Health. "Together with a recently established access program by the National Health Service in England and existing public reimbursement for the Oncotype DX breast cancer test in Switzerland, Ireland, Greece, Spain and Czech Republic, we continue to pioneer the delivery of value-based testing to healthcare systems across Europe."

The updated AGO guidelines reflect newly published large prospective Oncotype DX outcomes studies including TAILORx, conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI), and three-year data from the PlanB study, conducted by the West German Study Group (WSG). Five-year results from PlanB were presented on Friday, March 11 at a plenary session during the 10th European Breast Cancer Conference (EBCC-10).

Back